Cue Biopharma Deal History & Licensing Activity
Cue Biopharma is a biotech. Over the past three years, Cue Biopharma has been involved in 3 licensing and acquisition transactions, with a primary focus on Antibodies (2 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Antibodies
Focus Area
Dermatology
Cue Biopharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Cue Biopharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Ascendant-221 / CUE-221 | Ascendant Health / Genesis Life Sciences | Antibodies | Phase 2 | license | Apr 30, 2026 |
| CUE-100 series | ImmunoScape | Cell Therapy | Preclinical | collaboration | Nov 6, 2025 |
Cue Biopharma Pipeline Focus
Therapeutic areas and modalities where Cue Biopharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Cue Biopharma Strategic Signals
Key indicators of Cue Biopharma's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Cue Biopharma's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Dermatology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Cell Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for cell therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Cue Biopharma Licensing & Deal Activity
Cue Biopharma is a biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Cue Biopharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Cue Biopharma include Dermatology (2 deals and trials), Oncology (2 deals and trials), and Immunology (1 deal and trial). In terms of modality, Cue Biopharma has shown particular interest in antibodies, cell therapy, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Cue Biopharma and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Cue Biopharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.